InvaGen Launching Naproxen DR Tablets…..

InvaGen Pharmaceuticals launching FDA approved Naproxen Delayed-release Tablets USP 375 mg and 500 mg

Naproxen tablets are indicated:

 

• For the relief of the signs and symptoms of rheumatoid arthritis
• For the relief of the signs and symptoms of osteoarthritis
• For the relief of the signs and symptoms of ankylosing spondylitis
• For the relief of the signs and symptoms of juvenile arthritis

Naproxen tablets are also indicated:

 

• For relief of the signs and symptoms of tendonitis
• For relief of the signs and symptoms of bursitis
• For relief of the signs and symptoms of acute gout
• For the management of pain
• For the management of primary dysmenorrhea

InvaGen Launching Naproxen Tablets…..

InvaGen Pharmaceuticals launching FDA approved Naproxen Tablets USP 250 mg, 375 mg and 500 mg.

Naproxen tablets are indicated:

 

• For the relief of the signs and symptoms of rheumatoid arthritis
• For the relief of the signs and symptoms of osteoarthritis
• For the relief of the signs and symptoms of ankylosing spondylitis
• For the relief of the signs and symptoms of juvenile arthritis

 Naproxen tablets are also indicated:

 

• For relief of the signs and symptoms of tendonitis
• For relief of the signs and symptoms of bursitis
• For relief of the signs and symptoms of acute gout
• For the management of pain
• For the management of primary dysmenorrhea

InvaGen launching Quinapril HCl and HCTz Tablets….

InvaGen Pharmaceuticals launching FDA approved Quinapril Hydrochloride and Hydrochlorothiazide Tablets, 10/12.5 mg, 20/12.5 mg and 20/25 mg.

Quinapril HCl and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension.

 

In using quinapril HCl and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk.